{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.751","upperLimit":"3.779","value":"3.779"},{"comment":"Participant was alive at last contact.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG002","lowerLimit":"2.826","upperLimit":"2.826","value":"2.826"},{"groupId":"OG003","lowerLimit":"10.218","upperLimit":"10.218","value":"10.218"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"}],"units":"Participants"}],"description":"Kaplan-Meier method will be used to evaluate median overall OS and will be reported with a 95% confidence interval. Overall survival (OS) is defined as the time from the start of the treatment until time of death from any cause, for up to 3 years after completion of therapy, assessed every 3 months (±2 weeks).","dispersionType":"95% Confidence Interval","groups":[{"description":"Ended treatment at the regular dose level: 80 intravenous (IV)/80 Intraperitoneal (IP) + 300 twice a day (BID).","id":"OG000","title":"Intravenous Paclitaxel Dose Level 1, Intraperitoneal Paclitaxel Dose Level 1, Nilotinib Dose Level 1"},{"description":"Had the planned doses for Intraperitoneal (IP) Paclitaxel (80 IP) and by mouth (PO) nilotinib (300 twice a day (BID) but declined to go up to the 80mg/m\\^2 of intravenous (IV) Paclitaxel.","id":"OG001","title":"Intravenous Paclitaxel DoseLevel -1, Intraperitoneal Paclitaxel Dose Level 1, Nilotinib Dose Level 1"},{"description":"Had the planned doses for intravenous (IV) and Intraperitoneal (IP) Paclitaxel (80 IV/80 IP) but had a dose reduction for Nilotinib (400 every day (QD).","id":"OG002","title":"Intravenous Paclitaxel DoseLevel 1, Intraperitoneal Paclitaxel Dose Level 1, Nilotinib Dose Level -1"},{"description":"Had the planned dose of Intraperitoneal (IP) Paclitaxel (80 IP) but had a dose reduction for intravenous (IV) Paclitaxel (60 IV), and a dose reduction for Nilotinib (400 every day (QD).","id":"OG003","title":"Intravenous Paclitaxel DoseLevel -1, Intraperitoneal Paclitaxel DoseLevel 1, Nilotinib Dose Level -1"}],"paramType":"MEDIAN","populationDescription":"6/21 participants were analyzed because one participant was alive at last contact, including at study closure,12 were not treated and 2 refused further treatment.","reportingStatus":"POSTED","timeFrame":"From time of initiation of study treatment to death or last follow-up, a median of 5.60 months","title":"Median Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}